SS Innovations International, Inc. - Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. SS Innovations International, Inc. (SSi) is a commercial-stage surgical robotics company developing the "SSi Mantra" system. The company is a smaller reporting company and a non-accelerated filer.
Critical Disclosure: The filing includes an Explanatory Note stating that the Company's previously audited financial statements for 2022 and 2023, as well as interim statements for 2023 and Q1 2024, must be restated due to material accounting errors discovered during an internal review and reaudit by the new auditor, BDO India LLP. Consequently, the financial statements in this report are unaudited and prepared without the required auditor review or a restated balance sheet as of December 31, 2023. Management has concluded that disclosure controls and internal controls over financial reporting were not effective as of September 30, 2024.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|
| Total Revenue | $3,408,706 | $15,025,717 | $4,866,287 |
| Gross Profit | $1,302,677 | $5,419,839 | $751,462 |
| Net Loss | $(6,119,381) | $(11,699,076) | $(4,060,806) |
| Operating Loss | $(5,936,069) | $(11,347,303) | $(3,434,497) |
| Cash & Equivalents | $220,364 (Sep 30, 2024) | ||
| Restricted Cash | |||
| Total Assets | $37,811,974 (Sep 30, 2024) | ||
| Total Liabilities | $23,919,989 (Sep 30, 2024) | ||
| Stockholders' Equity | $13,891,985 (Sep 30, 2024) |
Debt & Liquidity: The company holds a Bank Overdraft Facility of $7,088,307 and Notes Payable of $4,950,000. Working capital surplus is reported at $7,722,657.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased significantly to $15.0M for the nine months ended Sept 30, 2024, compared to $4.9M in the prior year period. This is driven by the sale of 25 surgical robotic systems (including exports to Nepal, Indonesia, and Ecuador) and increased recurring revenue from instruments.
- Expense Surge: Operating expenses rose sharply to $16.8M (YTD 2024) from $4.2M (YTD 2023). The primary driver was Stock Compensation Expense, which totaled $6.6M for the nine months ended Sept 30, 2024, compared to $0 in the prior year period.
- Net Loss Expansion: Net loss widened to $11.7M (YTD 2024) from $4.1M (YTD 2023), primarily attributable to the non-cash stock compensation charges and increased R&D and G&A expenses associated with scaling operations.
- Balance Sheet: Total assets increased to $37.8M from $30.8M (restated Dec 31, 2023), while liabilities more than doubled to $23.9M due to new debt financing and accrued liabilities.
Guidance, Outlook, Risks, and Unusual Items
- Outlook: Management expects to require substantial funds for expansion, manufacturing capacity, and global clinical trials. Regulatory approvals in the US and EU are anticipated in late 2025. The company launched the "SSi Mantra 3" in Q3 2024.
- Going Concern: Financial statements are prepared on a going concern basis. While the company has raised $4.95M in short-term debt recently, there are no committed sources of future funding. Failure to secure capital could force a curtailment of expansion plans.
- Internal Control Weaknesses: The company identified material weaknesses including failure to apply U.S. GAAP properly, lack of written internal control documentation, and insufficient segregation of duties. A new ERP system is being implemented to remediate these issues.
- Legal Proceedings: Litigation is pending in the Bahamas regarding a 9% ownership interest in a subsidiary (Otto Pvt. Ltd.) involving the CEO. An interim court order maintains the status quo. The CEO has agreed to indemnify the company for related costs.
- Unusual Items: The filing is unaudited due to the ongoing reaudit of prior periods. The company is filing this report to comply with OTC market requirements pending the completion of the reaudit and subsequent amendments.
Investor Verification Checklist
- Restatement Status: Verify the timeline and expected impact of the restatement for 2022, 2023, and Q1-Q3 2024 financials once the BDO reaudit is complete.
- Stock Compensation: Review the specific terms of the stock grants and options issued in late 2023/early 2024 that drove the $6.6M expense, as this is a non-cash item significantly impacting net loss.
- Liquidity Runway: Assess the company's ability to service its $7.1M bank overdraft and $5.0M in notes payable given the lack of committed long-term funding.
- Revenue Quality: Confirm the collectability of the $7.5M in accounts receivable, noting that $2.4M is classified as long-term due to deferred payment terms.
- Legal Risk: Monitor the outcome of the Bahamian litigation regarding the Otto subsidiary, which could impact corporate structure or ownership.